Skip to main content
Delfa

← All trials/NCT01550653

CompletedPhase 1

Liraglutide Effects on Memory in Healthy Subjects

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

-

Actual enrollment

40

Study population

Healthy volunteers

Eligibility highlights

•BMI 19-25•Male

Primary endpoints

•The immediate and delayed recall of a declarative memory task•The immediate and delayed recall of an Episodic Memory Task (story recall)•Performance on a two-dimensional object location task on day 1 and day 35

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01550653
Org study IDOtt-NN-001

Timeline

Milestones

Study first posted2012-03-12estimated
Last update posted2014-02-27estimated
Study start2012-05 (month precision)
Primary completion2013-12actual (month precision)
Study completion2013-12actual (month precision)

Assets

Investigational agents

Liraglutide

Who this study enrolls

Healthy volunteers

Who can enroll

Minimum age18 Years
Maximum age35 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•Male sex
•Age 18-35 years
•Body mass index between 19 and 25 kg/m2
•Non-smoker

Exclusion criteria

•Receipt of any drug within 4 weeks prior to this trial
•Any known acute or chronic disease of the brain, heart, lung, kidney,liver, pancreas or gastrointestinal tract, any metabolic, endocrine or psychiatric disease.
•Brady- and Tachycardia, i.e. heart rate < 50 and > 90 beats per minute.
•Hypertension (systolic blood pressure > 150 mmHg, diastolic blood pressure > 90 mmHg).
•Hyperlipidemia (cholesterol, LDL, triglyceride > two times the upper reference limit based on analysis from the central laboratory)
•Impaired hepatic function measured as alanine aminotransferase (ALAT) > two times the upper reference limit based on analysis from the central laboratory
•Impaired renal function measured as creatinine > 120 µmol/l based on analysis from the central laboratory
•Family history of diabetes
•History of any eating disorder
•Known or suspected allergy to trial products
•History of drug or alcohol abuse within the last five years prior to screening

Endpoints (7)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
5
Glycemic / diabetes
1
Other (unclassified)
1

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint/low confidence

Change from baseline in serum/plasma concentrations of parameters involved in glucose metabolism on day 1,7,28, and 35.

Time frame:Day -7, 1, 7, 28, 35

change from baseline, improvement

Other clinical outcomes

5 endpoints
Primary/protocol endpoint

Change from Baseline in the immediate and delayed recall of a declarative memory task (word list recall) at time points indicated in "time frame" section.

Time frame:Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 1 (Immediate Recall 2), Day 7 (Delayed Recall 2), Day 28 (Immediate Recall 3), Day 35 (Delayed Recall 3)

change from baseline, improvement

Primary/protocol endpoint

Change from baseline in the immediate and delayed recall of an Episodic Memory Task (story recall) at the time points indicated in the "Time Frame" - section.

Time frame:Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change from baseline in performance on a two-dimensional object location task on day 1 and day 35.

Time frame:Day -7, Day 1, Day 35

change from baseline, improvement

Primary/protocol endpoint

Change from baseline in performance on a working-memory task on day 1 and day 35.

Time frame:Day -7, Day 1, Day 35

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change from baseline in immediate and delayed recall of a procedural memory task at the time points indicated in the "Time Frame" - section.

Time frame:Day -7 (immediate Recall 1), Day 0 (Delayed Recall 1), Day 28 (Immediate Recall 2), Day 35 (Delayed Recall 2)

change from baseline, improvement

Other (unclassified)

1 endpoint
Secondary/protocol endpoint/low confidence

Change from baseline in resting metabolic rate on day 7, 28 and 35.

Time frame:Day 0 , Day 7 , Day 28 , Day 35

change from baseline, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.